Half-year report · Q2

Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥251m2025-01-01 → 2025-06-30Cons.Net sales
Revenue¥636m2024-01-01 → 2024-12-31Cons.Net sales (5-year summary)
Revenue¥316m2024-01-01 → 2024-06-30Cons.Net sales
Operating income−¥1.1bn2025-01-01 → 2025-06-30Cons.Operating income
Operating income−¥1.1bn2024-01-01 → 2024-06-30Cons.Operating income
Ordinary income−¥1.1bn2025-01-01 → 2025-06-30Cons.Ordinary income
Ordinary income−¥2.1bn2024-01-01 → 2024-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.1bn2024-01-01 → 2024-06-30Cons.Ordinary income
Profit before tax−¥1.1bn2025-01-01 → 2025-06-30Cons.Income before income taxes
Profit before tax−¥1.1bn2024-01-01 → 2024-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.2bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss
Net income−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss
Total assets¥1.6bnat 2025-06-30Cons.Assets
Total assets¥2.8bnat 2024-12-31Cons.Assets
Total assets¥3.7bnat 2024-06-30Cons.Total assets (5-year summary)
Total liabilities¥244mat 2025-06-30Cons.Liabilities
Total liabilities¥297mat 2024-12-31Cons.Liabilities
Net assets / equity¥1.4bnat 2025-06-30Cons.Net assets
Net assets / equity¥2.5bnat 2024-12-31Cons.Net assets
Net assets / equity¥3.2bnat 2024-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.1bnat 2025-06-30Cons.Cash and deposits
Cash and deposits¥2.1bnat 2024-12-31Cons.Cash and deposits
Cash & equivalents¥1.1bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31vCons.Cash and cash equivalents
Operating cash flow−¥995m2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥222m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥16m2025-01-01 → 2025-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13m2024-01-01 → 2024-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥14m2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥567m2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥279m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-55.292025-01-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-121.642024-01-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-63.252024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio85.1%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.3%at 2024-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio87.2%at 2024-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥251m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥251m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥51m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥1.1bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥24m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 418
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任監査法人トーマツ
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)西  方     実
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)安 場 達 哉
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration315642000JPY
Net sales (5-year summary)CurrentYTDDuration251097000JPY
Net sales (5-year summary)Prior1YearDuration636235000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration-1087156000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration-1055024000JPY
Ordinary income loss (5-year summary)Prior1YearDuration-2080739000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration-1094118000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration-1056054000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration-2178576000JPY
Comprehensive income (5-year summary)Prior1YTDDuration-1026469000JPY
Comprehensive income (5-year summary)CurrentYTDDuration-1086224000JPY
Comprehensive income (5-year summary)Prior1YearDuration-2144646000JPY
Net assets (5-year summary)Prior1QuarterInstant3215316000JPY
Net assets (5-year summary)CurrentQuarterInstant1391122000JPY
Net assets (5-year summary)Prior1YearInstant2475354000JPY
Total assets (5-year summary)Prior1QuarterInstant3685650000JPY
Total assets (5-year summary)CurrentQuarterInstant1635585000JPY
Total assets (5-year summary)Prior1YearInstant2772115000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration-63.25
Basic earnings loss per share (5-year summary)CurrentYTDDuration-55.29
Basic earnings loss per share (5-year summary)Prior1YearDuration-121.64
Diluted earnings per share (5-year summary)Prior1YTDDuration-
Diluted earnings per share (5-year summary)CurrentYTDDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.872
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.851
Equity to asset ratio (5-year summary)Prior1YearInstant0.893
Net cash provided by used in operating activities (5-year summary)Prior1YTDDuration-222059000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYTDDuration-994641000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration-1374806000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YTDDuration-7108000JPY
Net cash provided by used in investing activities (5-year summary)CurrentYTDDuration-15884000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration-13060000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YTDDuration279068000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYTDDuration-14006000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration567441000JPY
Cash and cash equivalents (5-year summary)Prior1QuarterInstant3026030000JPY
Cash and cash equivalents (5-year summary)CurrentQuarterInstant1060569000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant2108484000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember19115500
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember19115500
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant19115500
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant19115500
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember809212
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.0423

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-12-31pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass